The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by the ...

Emergent BioSolutions Inc (EBS) reports a robust financial performance with a 9% revenue increase and significant debt reduction, despite challenges in Narcan sales.

Q3 2024 Earnings Call Transcript November 6, 2024 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Thursday after the company reported strong third-quarter results, lifting retail sentiment. Earnings per share for Q3 came in ...

HAL reported a third-quarter revenue decline of 1.8% year-over-year to $5.697 billion, missing the consensus of $5.828 ...

Emergent BioSolutions expects a 2024 net loss of $203 million-$183 million, down from the previous loss range of $314 million ...

At this time, I would like to welcome everyone to the Q3 2024 Emergent BioSolutions Inc. earnings conference call. All lines ...